Mizugaki et al. demonstrated that CD133 expression was associated with poor prognosis in a study of 161 NSCLC patients, and Wu et al. explained in a meta-analysis conducted on 23 studies, that CD133 could be a potential prognostic marker in NSCLC (24, 25). Here, PROM1 is linked to non-small cell lung carcinoma.